Skip to main content
. 2018 Feb 16;107(4):271–280. doi: 10.1007/s00392-018-1202-x

Fig. 2.

Fig. 2

Cardiac monitoring of patients during potentially cardiotoxic cancer therapy. *Reassessment with discontinuation of cardiotoxic therapy vs. dose reduction vs. change of chemotherapeutic drug vs. unmodified continuation of oncologic treatment. **Optional. BP blood pressure measurement, ECG electrocardiogram, LVEF left ventricular ejection fraction, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, ASA acetylsalicylic acid

HHS Vulnerability Disclosure